These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

524 related items for PubMed ID: 24846518

  • 21. Scalp psoriasis and biologic agents: a retrospective, comparative study from a tertiary psoriasis referral centre.
    Fotiadou C, Lazaridou E, Sotiriou E, Kyrgidis A, Apalla Z, Ioannides D.
    J Eur Acad Dermatol Venereol; 2016 Dec; 30(12):2091-2096. PubMed ID: 27406435
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
    Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM.
    J Am Acad Dermatol; 2010 Sep; 63(3):448-56. PubMed ID: 20605254
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study.
    Papp K, Ho V, Teixeira HD, Guerette B, Chen K, Lynde C.
    J Eur Acad Dermatol Venereol; 2012 Aug; 26(8):1007-13. PubMed ID: 22023702
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Efalizumab in the Treatment of Scalp, Palmoplantar and Nail Psoriasis: Results of a 24-Week Latin American Study.
    Takahashi MD, Chouela EN, Dorantes GL, Roselino AM, Santamaria J, Allevato MA, Cestari T, de Aillaud ME, Stengel FM, Licu D.
    Arch Drug Inf; 2010 Mar; 3(1):1-8. PubMed ID: 20428227
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Relationship of psoriatic arthritis with nail and scalp involvement in Turkish psoriasis patients: Multicentered cross-sectional study.
    Askin O, Engin B, Ozdede A, Kartal SP, Ugurlu S, Akbulut TO, Ekinci AP, Aydogdu İH, Ozden MG, Kok H, Dogan S, Ozturkcan S, Borlu M, Baskan EB, Yilmaz N, Ak T, Topkarci Z, Serdaroglu S.
    Medicine (Baltimore); 2024 Jul 19; 103(29):e38832. PubMed ID: 39029037
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study.
    Thaçi D, Ortonne JP, Chimenti S, Ghislain PD, Arenberger P, Kragballe K, Saurat JH, Khemis A, Sprøgel P, Esslinger HU, Unnebrink K, Kupper H.
    Br J Dermatol; 2010 Aug 19; 163(2):402-11. PubMed ID: 20377585
    [Abstract] [Full Text] [Related]

  • 30. Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis.
    Orbai AM, Chakravarty SD, You Y, Shawi M, Yang YW, Merola JF.
    Dermatol Ther (Heidelb); 2023 Nov 19; 13(11):2859-2868. PubMed ID: 37713133
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB.
    J Am Acad Dermatol; 2017 Mar 19; 76(3):418-431. PubMed ID: 28057361
    [Abstract] [Full Text] [Related]

  • 32. Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2).
    Papp KA, Gerdes S, Leonardi CL, Elmaraghy H, See K, McKean-Matthews M, Konicek BW, Crane HM, Eastman W.
    J Drugs Dermatol; 2021 Aug 01; 20(8):880-887. PubMed ID: 34397207
    [Abstract] [Full Text] [Related]

  • 33. Effectiveness and safety of apremilast in biologic-naïve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL study.
    Ioannides D, Antonakopoulos N, Georgiou S, Chasapi V, Katsantonis I, Drosos A, Rigopoulos D, Antoniou C, Anastasiadis G, Bassukas I, Ioannidou D, Protopapa A, Neofotistou O, Krasagakis K, Aronis P, Papageorgiou M, Lazaridou E, Patsatsi A, Lefaki I, Roussaki-Schulze AV, Satra F, Anagnostopoulos Z, Papakonstantis M.
    J Eur Acad Dermatol Venereol; 2021 Sep 01; 35(9):1838-1848. PubMed ID: 34036627
    [Abstract] [Full Text] [Related]

  • 34. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials.
    Blauvelt A, Sofen H, Papp K, Gooderham M, Tyring S, Zhao Y, Lowry S, Mendelsohn A, Parno J, Reich K.
    J Eur Acad Dermatol Venereol; 2019 Dec 01; 33(12):2305-2312. PubMed ID: 31407394
    [Abstract] [Full Text] [Related]

  • 35. Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study.
    Kyriakou A, Patsatsi A, Sotiriadis D.
    J Dermatolog Treat; 2013 Jun 01; 24(3):162-8. PubMed ID: 22136334
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H, Nakagawa H, Nakajo K, Ishii T, Morisaki Y, Aoki T, Cameron GS, Osuntokun OO, Japanese Ixekizumab Study Group.
    J Dermatol; 2017 Apr 01; 44(4):355-362. PubMed ID: 27726163
    [Abstract] [Full Text] [Related]

  • 37. Short-Term Correlation of the Psoriasis Area Severity Index, the Nail Psoriasis Area Severity Index, and the Dermatology Life Quality Index, before and after Treatment, in Patients with Skin and Nail Psoriasis.
    Prevezas C, Katoulis AC, Papadavid E, Panagakis P, Rigopoulos D.
    Skin Appendage Disord; 2019 Nov 01; 5(6):344-349. PubMed ID: 31799260
    [Abstract] [Full Text] [Related]

  • 38. The Brigham Scalp Nail Inverse Palmoplantar Psoriasis Composite Index (B-SNIPI): a novel index to measure all non-plaque psoriasis subsets.
    Patel M, Liu SW, Qureshi A, Merola JF.
    J Rheumatol; 2014 Jun 01; 41(6):1230-2. PubMed ID: 24882859
    [Abstract] [Full Text] [Related]

  • 39. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL.
    Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH.
    J Am Acad Dermatol; 2012 Feb 01; 66(2):241-51. PubMed ID: 21752491
    [Abstract] [Full Text] [Related]

  • 40. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
    Rich P, Gooderham M, Bachelez H, Goncalves J, Day RM, Chen R, Crowley J.
    J Am Acad Dermatol; 2016 Jan 01; 74(1):134-42. PubMed ID: 26549249
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.